Tesofensine
Tesofensine (triple monoamine reuptake inhibitor)
An investigational non-peptide weight-loss drug that suppresses appetite by acting on brain neurotransmitters.
Overview
Tesofensine is a small-molecule inhibitor of the reuptake of noradrenaline, dopamine, and serotonin, originally studied for Parkinson's and Alzheimer's before its appetite-suppressing effect drew attention. Phase 2 obesity trials showed substantial weight loss. It is not a peptide and is not approved, but it appears on peptide and longevity resources as a weight-loss compound.
Mechanism of action
Blocks reuptake of noradrenaline, dopamine, and serotonin, increasing satiety signaling and reducing food intake.
Key studies & citations
- Human2008
Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial
Phase 2, 203 patients: 4.5%, 9.2% and 10.6% weight loss at 24 weeks versus 2.0% with placebo; heart rate rose 7.4 bpm at 0.5 mg.
The Lancet - Human2012
The effect of tesofensine on appetite sensations
Phase 2 sub-study: weight loss was driven mainly by reduced appetite and energy intake.
Obesity
Frequently asked questions
Is tesofensine a peptide?
No. It is a small-molecule brain-active drug. It is included because it appears on peptide and weight-loss resources as an investigational obesity compound.